Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
Rock Springs Capital Management LP sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in Q4, an estimated $5.59 million transaction due to the stock's 50% crash in November after a clinical trial setback. The fund's stake in Agios now represents 1.12% of its AUM, a reduction from 2.2% in the prior quarter, as the stock has fallen 16% over the past year.
Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO
Eagle Health Investments LP significantly reduced its stake in Agios Pharmaceuticals (NASDAQ: AGIO) by selling 84,600 shares, a 25.6% trim, now holding 246,230 shares valued at approximately $9.88 million. Despite this, several analysts have recently raised their price targets on AGIO, contributing to a "Hold" average rating with an average target price of $39.78. Meanwhile, company insiders have also sold a total of 33,303 shares in the last quarter, representing a 4.93% ownership in the company.
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
Agios Pharmaceuticals saw its stock drop 16% over the past year, significantly underperforming the S&P 500, following a 50% crash in November due to a clinical trial setback. Rock Springs Capital Management consequently reduced its stake in Agios by 159,379 shares, totaling an estimated $5.59 million. This transaction decreased Agios's representation in the fund's assets under management from 2.2% to 1.12%.
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North
The global Alpha Thalassemia Market is projected to reach US$ 1.9 billion by 2031, growing from US$ 1.1 billion in 2022 at a CAGR of 7.4%. North America is expected to lead with a 35% market share, driven by advanced healthcare infrastructure and genetic testing. Key market drivers include the increasing prevalence of genetic blood disorders, diagnostic advancements, and growing awareness, with major companies like Agios Pharmaceuticals, Actis, and Novartis Pharmaceuticals Corporation shaping the market through therapeutic innovation and expanded access.
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO)
RBC Capital analyst Luca Issi maintained a Hold rating on Agios Pharma (AGIO) with a price target of $28.00, according to a report on February 12. Despite this, Truist Financial reiterated a Buy rating on AGIO on the same day. Agios Pharma reported a quarterly revenue of $12.88 million and a GAAP net loss of $103.43 million for the quarter ending September 30.
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress
Agios Pharmaceuticals (AGIO) saw its stock rise 5.4% following the release of its 2025 full-year results, which showed a revenue increase but a swing to a net loss. The company achieved a significant milestone with the U.S. launch of AQVESME for thalassemia, contributing to stronger-than-expected quarterly revenues. The mixed financial results and the successful product launch are shaping the company's investment narrative, especially concerning its pyruvate kinase activation platform and future clinical trial progress.
Wall Street Zen Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold
Wall Street Zen has upgraded Agios Pharmaceuticals (NASDAQ:AGIO) from "sell" to "hold." This upgrade follows Agios's Q4 results, which exceeded expectations with strong PYRUKYND sales and the recent U.S. approval of AQVESME. Despite positive clinical and commercial milestones, the company remains unprofitable and has seen insider selling, leading to a mixed outlook among analysts.
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss
Agios Pharmaceuticals (AGIO) reported a Q4 2025 loss of $1.85 per share, which was narrower than anticipated, and total revenues of $20 million, exceeding estimates. The company's lead drug, mitapivat (marketed as Pyrukynd and Aqvesme), contributed significantly to product revenues, with strong performance in the U.S. and initial inventory stocking internationally. Agios also provided updates on its pipeline, including plans to engage with the FDA for mitapivat in sickle cell disease and upcoming results for tebapivat in the same indication.
Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives
Agios Pharmaceuticals reported a Q3 FY 2025 net loss of US$103.4 million on revenues of US$12.9 million, reinforcing concerns about its profitability. The company's trailing twelve-month revenue stands at US$44.8 million with a net loss of US$401.3 million, driven by high R&D and SG&A spending. While bulls point to forecast revenue growth of 49.1% and a DCF fair value significantly above the current share price, bears highlight persistent losses and the lack of projected short-term profitability, with forecasts suggesting losses for at least three more years.
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight
Agios Pharmaceuticals Inc (AGIO) reported strong Q4 2025 results, with PYRUKYND revenue growing 86% year-over-year to $20 million and full-year revenue reaching $54 million. The company successfully launched AQVESME for thalassemia, receiving 44 prescriptions in the first five weeks, and ended 2025 with $1.2 billion in cash. Despite increased R&D expenses and
Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Beats Expectations By $0.11 EPS
Agios Pharmaceuticals reported stronger-than-expected Q4 earnings, with an EPS of ($1.85) against an estimate of ($1.96), and revenue significantly surpassing expectations at $19.97 million compared to $12.06 million. The company highlighted commercial momentum for ACTIVASE and PYRUKYND, along with multiple upcoming R&D catalysts and a stated path to profitability, ending 2025 with $1.2 billion in cash. AGIO's stock traded up following the announcement, though insider selling and analyst rating adjustments were also noted.
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report
AGIOS PHARMACEUTICALS, INC. (AGIO) has released its annual 10-K report detailing its financial performance, business operations, and strategic initiatives. Key highlights include total revenue of $54.0 million in 2025, significant net income changes due to asset sales in prior years, and operating expenses of $526.2 million in 2025. The company also announced new product launches, regulatory approvals, and pipeline expansion for genetically defined diseases, while outlining challenges such as market acceptance, regulatory risks, and competition.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) reported a Q4 loss of $1.85 per share, surpassing the Zacks Consensus Estimate of a $1.97 loss. The company's revenues for the quarter reached $19.97 million, exceeding estimates by 94.14% and marking a significant increase from the previous year. Despite outperforming the market year-to-date, AGIO currently holds a Zacks Rank #3 (Hold).
Agios Pharmaceuticals: Fourth Quarter Earnings Overview
Agios Pharmaceuticals reported a net loss of $108 million, or $1.85 per share, for the fourth quarter, outperforming analyst expectations of a $1.97 per share loss. The biopharmaceutical company generated $20 million in revenue, exceeding the $10.3 million forecast. For the full year, Agios reported a total loss of $412.8 million ($7.12 per share) on $54 million in revenue, with its shares rising almost 2% year-to-date but down 15% over the past twelve months.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss
Agios Pharmaceuticals (NASDAQ:AGIO) reported a strong Q4 2025 showing a revenue beat of $20.0 million against estimated $12.3 million, and a narrower-than-expected Non-GAAP EPS loss of -$1.85. The positive results, driven by their lead product PYRUKYND®, led to a significant 3.03% increase in pre-market trading, countering recent stock weakness. The company's future performance will depend on its ability to maintain commercial momentum and advance its pipeline.
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M
Agios Pharmaceuticals, Inc. (AGIO) announced Q4 revenue of $20.0 million, significantly exceeding the FactSet estimate of $12.1 million. The biopharmaceutical company focuses on developing therapies for rare diseases, with its lead product candidate, PYRUKYND (Mitapivat), an activator for pyruvate kinase deficiency and other hemolytic anemias. The company is actively conducting clinical trials for Mitapivat in various conditions and developing another clinical-stage activator, AG-946.
Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia
Agios Pharmaceuticals announced fourth-quarter 2025 revenues of $20 million and full-year revenues of $54 million, largely due to strong sales of PYRUKYND® and the newly FDA-approved AQVESME™ for thalassemia. The company reported a net loss of $108 million for Q4 2025 but maintains a strong cash position of $1.2 billion. Agios also plans a pre-sNDA meeting with the FDA for mitapivat in sickle cell disease and expects Phase 2 results for tebapivat in late 2026.
Agios Pharmaceuticals: Fourth Quarter Earnings Overview
Agios Pharmaceuticals reported a Q4 net loss of $108 million, or $1.85 per share, but still surpassed analyst expectations. The biopharmaceutical firm's revenue reached $20 million, exceeding projections. Despite annual losses, Agios shares have seen a nearly 2% rise year-to-date, though they are down 15% over the past year.
Agios Pharmaceuticals: Q4 Earnings Snapshot
Agios Pharmaceuticals Inc. (AGIO) reported a Q4 loss of $108 million, or $1.85 per share, which exceeded Wall Street's expectations. The biopharmaceutical company also surpassed revenue forecasts, posting $20 million for the period. For the full year, the company had a loss of $412.8 million on $54 million in revenue.
Agios Pharmaceuticals: Q4 Earnings Snapshot
Agios Pharmaceuticals Inc. reported a Q4 loss of $108 million, or $1.85 per share, surpassing Wall Street expectations which anticipated a loss of $1.97 per share. The biopharmaceutical company also exceeded revenue forecasts, posting $20 million against an expected $10.3 million. For the full year, Agios Pharmaceuticals recorded a loss of $412.8 million on revenues of $54 million.
Agios Pharmaceuticals: Q4 Earnings Snapshot
Agios Pharmaceuticals Inc. reported a Q4 loss of $108 million, or $1.85 per share, which was better than Wall Street's expectation of a $1.97 per share loss. The biopharmaceutical company also exceeded revenue forecasts, posting $20 million against an expected $10.3 million. For the full year, Agios Pharmaceuticals recorded a loss of $412.8 million, or $7.12 per share, and its stock has climbed nearly 2% year-to-date while dropping 15% over the last 12 months.
Avoiding Lag: Real-Time Signals in (AGIO) Movement
This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock movement, highlighting weak near-term sentiment and a mid-channel oscillation pattern. It presents three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis indicating support and resistance. The report emphasizes the exceptional 105.1:1 risk-reward setup targeting a 28.8% gain.
Agios Pharm set to report earnings amid thalassemia drug rollout By Investing.com
Agios Pharmaceuticals is scheduled to report its Q4 and full-year 2025 earnings, with investors closely watching the commercial rollout of its newly approved thalassemia drug, AQVESME. Analysts anticipate a loss of $1.95 per share on revenues of $12.06 million for the fourth quarter. The company's pipeline for sickle cell disease treatment and expense management will also be key areas of focus for profitability.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Hold" from Analysts
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $39.44 based on one sell, four hold, and six buy ratings. Recent insider selling by CEO Brian Goff and CFO Cecilia Jones totaled 33,503 shares worth approximately $910,745. The company's stock trades at $26.53, with a market cap of $1.55 billion, and insiders currently own 4.93% of the shares.
Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness
Agios Pharmaceuticals (AGIO) has experienced significant share price weakness, with its stock down 35% over the past three months and a 22.8% loss over the last year. Despite trading at a discount to analyst targets and showing some improvement in annual revenue trends, concerns remain regarding its high P/S ratio compared to industry averages and the heavy reliance on future pipeline success, particularly with its drug PYRUKYND. The company's fair value is estimated at $36.75 per share, suggesting it is undervalued, but this hinges on the successful expansion and commercialization of its pipeline and managing ongoing high R&D and SG&A spending.
Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday
Agios Pharmaceuticals (AGIO) is projected to release its Q4 2025 earnings before market open on Thursday, February 12, 2026. Analysts anticipate an EPS of ($1.96) and revenue of $12.059 million. The stock currently has a "Hold" rating from Wall Street, with a consensus target price of $39.44, and recent insider selling has been noted from the CEO and other insiders.
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Crosses Below 200 Day Moving Average - Time to Sell?
Agios Pharmaceuticals (NASDAQ:AGIO) stock recently fell below its 200-day moving average, trading at $27.93 with a 200-day moving average of $34.67. Analysts have a mixed view with a consensus "Hold" rating and an average target price of $39.44, following various price target adjustments from firms like Leerink Partners, Bank of America, and The Goldman Sachs Group. Insider selling has also occurred, with key executives reducing their holdings, while institutional investors have made both new purchases and increased positions.
Discipline and Rules-Based Execution in AGIO Response
This article provides an AI-generated analysis of Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting weak near-term sentiment and a significant risk-reward setup. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and presents multi-timeframe signal analysis and support/resistance levels.
Agios lines up Feb. 12 webcast on 2025 earnings results
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) will host a conference call and live webcast on February 12, 2026, at 8:00 a.m. ET to release its fourth quarter and full year 2025 financial results and business highlights. The webcast will be available on the company’s Investors website under the "Events & Presentations" tab, with a replay posted approximately two hours after the event. Historically, similar announcements have led to modest, positive stock movements.
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC)
Three healthcare companies, Cardinal Health (CAH), Agios Pharma (AGIO), and Henry Schein (HSIC), have received bullish sentiments from analysts. Cardinal Health received a Strong Buy consensus with a target of $235.54, while Agios Pharma earned a Moderate Buy with a $36.14 target, and Henry Schein also has a Moderate Buy rating with a $79.75 target. These recommendations highlight potential upsides for investors in these stocks.
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35
BofA Securities analyst Alec Stranahan has maintained a Buy rating on Agios Pharmaceuticals (AGIO.US) and kept the target price at $35. TipRanks data indicates that Stranahan has a 53.7% success rate and an 8.7% average return over the past year. This report highlights analyst performance and provides informational context about the rating.
Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche
The Sickle Cell Disease (SCD) market, valued at approximately $650 million in 2023 across six major markets, is projected for steady growth until 2034, driven by advancements in gene therapy and personalized medicine. The US currently holds the largest market share. Upcoming therapies like CASGEVY and LYFGENIA are expected to be market leaders, while significant R&D efforts are underway by companies such as Beam Therapeutics, Pfizer, and Vascarta, despite some recent clinical trial setbacks.
Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record
Agios Pharmaceuticals (AGIO) has experienced recent short-term gains, but its long-term performance remains negative. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 75%, while a Price-to-Sales (P/S) ratio analysis indicates it is overvalued compared to industry and peer averages. Simply Wall St offers a "Narratives" feature to help investors reconcile these differing valuations based on their own assumptions about the company's future.
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst
Zacks Research has slightly increased its Q2 2026 EPS estimate for Agios Pharmaceuticals to ($1.95) from ($1.97), while maintaining a "Hold" rating on the stock. The firm also provided full-year 2026 EPS estimate of ($7.60), contrasting with the MarketBeat consensus of ($6.85). Despite significant net losses, Agios Pharmaceuticals recently surpassed Q3 2025 earnings expectations with an EPS of ($1.78) and revenue of $12.88 million, marking a 43.3% year-over-year increase.
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch
Agios Pharmaceuticals (AGIO) is under scrutiny after the FDA approval and U.S. launch of AQVESME for thalassemia, and ahead of further regulatory steps for mitapivat. Despite a recent stock rebound, AGIO has seen significant declines over the past year. While one analysis suggests it is 22.8% undervalued with a fair value of $36, another perspective notes its high P/S ratio compared to peers, indicating potential over-optimism.
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch
Agios Pharmaceuticals (AGIO) recently received FDA approval and launched AQVESME for thalassemia, with further regulatory steps for mitapivat in sickle cell disease expected. Despite recent stock volatility and a 90-day decline, the company aims for profitability, leading to a "most popular narrative" suggesting it is 22.8% undervalued. However, its high P/S ratio compared to peers indicates caution, and its path to profitability relies on future growth and broadening PYRUKYND into new indications, while managing risks from high R&D and SG&A expenses.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Agios Pharmaceuticals (NASDAQ:AGIO) has received a "Moderate Buy" consensus rating from analysts, with an average one-year target price of $39.44. This comes amidst analyst upgrades from Leerink and Truist, alongside price target reductions from Goldman Sachs and RBC. Despite a beat on last quarter's EPS and a 43.3% revenue increase, the company remains unprofitable, and insiders have sold shares totaling over $1 million in the last three months.
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)?
Agios Pharmaceuticals recently outlined its strategic priorities, focusing on the U.S. launch of AQVESME for thalassemia and advancing regulatory steps for mitapivat in sickle cell disease. This strategy aims to leverage mitapivat across multiple hematologic indications to drive commercial momentum and address ongoing losses. While the FDA approval of AQVESME underpins the launch, its concentrated reliance on mitapivat and its safety profile with REMS restrictions present both opportunities and risks, shaping the investment narrative for AGIO.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 worth of Agios Pharmaceuticals (NASDAQ:AGIO) stock on December 11th, according to a January 12th disclosure. This insider buying comes amidst a period where other insiders, including CEO Brian Goff, have been net sellers of AGIO shares. Agios Pharmaceuticals' stock saw a 3.3% increase following the news, and the company has a "Moderate Buy" consensus rating from analysts.
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Truist Financial analyst Gregory Renza has reiterated a "Buy" rating for Agios Pharmaceuticals (AGIO.US). Based on TipRanks data, Renza has demonstrated a 50.2% success rate and an average return of 23.2% over the past year. This rating comes as Agios Pharmaceuticals saw a 3.35% increase in its stock.
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)?
Agios Pharmaceuticals recently detailed its 2026 strategy, focusing on the U.S. launch of AQVESME for thalassemia and advancing regulatory steps for its use in sickle cell disease. Both initiatives are pivotal for transitioning its rare disease pipeline into commercial success and addressing ongoing financial losses. Investors should note the concentrated reliance on mitapivat and its REMS restricted safety profile as a key factor affecting the company's investment narrative.
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
On the second day of the J.P. Morgan Healthcare Conference (JPM26), several biopharma companies, including AstraZeneca, BioNTech, and Agios, presented their revenue and R&D targets stretching to the end of the decade. AstraZeneca reaffirmed its ambitious goal of achieving $80 billion in revenue by 2030 through new product launches and a strong pipeline, while BioNTech articulated its strategic shift from COVID-19 to oncology, focusing on its PD-1/VEGF bispecific antibody, pumitamig. Agios Pharmaceuticals aims for a $10 billion market opportunity by 2030 by expanding into broader rare disease portfolios, and Acadia Pharmaceuticals provided sales forecasts for its key drugs, exceeding analyst expectations.
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
TD Cowen analyst Marc Frahm has reiterated a Buy rating for Agios Pharmaceuticals (AGIO.US). Frahm has a 52.6% success rate and a 21.1% average return over the past year, according to TipRanks data. This rating is provided for informational purposes only and does not constitute investment advice.
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com
Agios Pharmaceuticals CEO Brian Goff sold 18,703 shares of common stock for a total of $506,663, while also exercising options to acquire 38,278 shares at no cost. This follows the FDA approval of their drug AQVESME for thalassemia, leading BofA Securities and H.C. Wainwright to raise their price targets for the company. Goff now directly owns 143,103 shares of the company.
Sickle Cell Disease Treatment Market is Thriving Worldwide | Novartis AG, Emmaus Medical Inc., Agios Pharmaceuticals Inc., Bluebird Bio
The Sickle Cell Disease Treatment Market is projected to grow from USD 3.20 billion in 2025 to USD 8.81 billion by 2032, exhibiting a CAGR of 15.6%. A detailed report by Coherent Market Insights highlights factors driving this growth, competitive analysis, and strategic opportunities for stakeholders. Key therapeutic areas include blood transfusion, bone marrow transplant, and pharmacotherapy.
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com
Agios Pharmaceuticals has commenced the U.S. commercial launch of AQVESME (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia, following its FDA approval in December 2025. The drug is the only FDA-approved treatment for both non-transfusion-dependent and transfusion-dependent forms of the condition and is expected to be available by late January 2026. Despite profitability challenges, analysts maintain a "Buy" recommendation with an average price target suggesting a 28% upside.
Agios begins U.S. launch of thalassemia drug following FDA approval
Agios Pharmaceuticals has launched AQVESME (mitapivat) in the U.S. for the treatment of anemia in adults with alpha- or beta-thalassemia, following FDA approval in December 2025. This makes AQVESME the only FDA-approved treatment for both non-transfusion-dependent and transfusion-dependent forms of the condition. Analysts maintain a "Buy" rating for Agios, with an average price target implying 28% upside.
New anemia pill and sickle cell trials set up big year in rare disease care
Agios Pharmaceuticals (AGIO) has outlined its strategic priorities for 2026, focusing on the commercialization of AQVESME (mitapivat) for thalassemia in the U.S. and advancing its pipeline of rare disease programs. The company expects to launch AQVESME in late January 2026, plans a pre-sNDA FDA meeting for mitapivat in sickle cell disease in Q1 2026, and anticipates several topline readouts across its pipeline. Agios projects a clear path to profitability and over $1 billion in peak global sales from its PK activation franchise.
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
Agios Pharmaceuticals announced its 2026 strategic priorities, focusing on the commercial launch of AQVESME™ (mitapivat) for thalassemia following its December 2025 FDA approval. The company also plans to submit a U.S. regulatory application for mitapivat in sickle cell disease and advance its early- and mid-stage pipeline for other high-value indications. Agios aims for profitability with over $1 billion in potential peak global sales, driven by its existing commercial presence and pipeline expansion.
Agios Pharmaceuticals Outlines 2026 Strategic Priorities and Milestones
Agios Pharmaceuticals announced its strategic priorities and key milestones for 2026, focusing on expanding its rare disease portfolio. Key highlights include the U.S. launch of AQVESME following FDA approval, a pre-sNDA meeting for mitapivat in sickle cell disease, and a target of over $1 billion in peak global sales. The company also plans to advance its early-stage pipeline and enhance operational efficiency.
